We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Any guess on sp when we get a good deal?
IMM gets the jitters when it gets around £10 m Market cap. I think we need a bit more good news to get this moving north.
York
My breakeven is now around 5.5p but had to buy a lot of shares to get it to that level.
Maybe not what the experts might advise but may as well be hanged for a sheep as a lamb.
ATB
Nice one Dallo. I am up to 1.3 million now at an average of 1.9 so fingers crossed.
Nice one dallo
When we have a flurry of buys an rns usually follows.
Fingers crossed 🤞
Gla
My order filled 250k at 2.40 to add to yesterday's 250k.
So now deeply immersed in Immupharma..fingers crossed.
Hard to get any shares at the moment in size .
I have an order in at 2.4p since 9oc but still no luck.
Hopefully we get some positive news soon
ATB
Formerlyeasyp - Firstly I disagree the gains are modest - IMM closed at just 0.85p on 4 March.
Secondly, I don't think it's "just optimism driven". Earler this year, there was real concern IMM would run out of cash, necessitating another placing.
Their 6 March RNS allayed those fears somewhat, stating "the financing position of the Company is sufficient for its immediate requirements and it has no current plans to raise equity through the capital markets". IMM's share price responded accordingly.
Admittedly, the exact wording in this RNS was somewhat qualified (IMMEDIATE requirements .... CURRENT plans). But it was better than nothing & helped reassure investors. For now at least.
While I am enjoying the modest gains it is imo just optimism driven and yes it has in turn generated a little upwards momentum.
We need hard scientific and business driven news to see a significant share price rise.
Seems to have settled around 2.30 mark for now.
Advise and input from the likes of Dr Muller and Dr Reilly are all part of Avion´s wish to reduce the probability of failure to the minimum possible thus safeguarding their trial investment .... and..as everyone knows...with these things every detail counts even the smallest ..and I doubt Avion will want to start the trial until they feel every detail has in fact been covered
Dallo et al
I really consider that the order will be trial timelines first, possibly patents arrangements next then deals.
Possible partners will want maximum detail before making best offers-IMM will need a 'good hand' to negotiate with.
GLA
Dallo,
Whilst we may rejoice in the recent SP increase from all time lows, the road remains long.
It's been quite a while since the Sp has gone above the benchmark Price on a monthly basis for IMM to receive the full monthly payment from Landstead .
It's also very encouraging that Prof. Muller is still implicated at her ripe young age of 72.
Hopefully we will get some updates on the 'start' of the Lupus trial shortly and that IMM will sign a major commercial deal in the near future.
Blue start to the day. Lets see where we go today.
Gla
I agree, dallo. It is positive that Lanstead continue to hold. Often forgotten amongst the negativity, that similar funding was in place prior to the last phase 3 when the shares rose from circa 20p to circa 180p, and many profited despite the doomsayers. Lanstead were the key player then too. Also, as you mention, the current share price buoyancy will increase the cash inflows from the agreement. ATB
The disconnected from what we have and our mcap shows that we are truely undervalued.
They will want to see it through....
At the AGM the lead science professionals made it clear that Prof Muller was in frequent contact with them-at least weekly.
This bodes well as does Dr Reilly's presence on main board.
GLA
Dallo;
Another valuable post from you about the scientific contribution Prof Sylvane Muller to IMM's principal drug asset, peptide platform P140.
It's her close involvement with IMM as inventor of P140 and Lupuzor, and her eminence in European science that first persuaded to invest in IMM in 2011. her continued close association also keeps me onboard.
As we know Professor Sylviane Muller , the inventor of Lupuzor, is according to the Immupharma website a key collaborator in the current trials for the drug.
She was awarded France's Legion d'honneur , the highest accolade in France in 2021 and there is a photo of the two Tims at the ceremony with her.
She is currently the Chair of Therapeutic Immunology at Strasbourg University and on the Board of France's
National Science Council among other prestigious positions.
Apparently she has worked on the reformulated Lupuzor drug following the extensive FDA discussions and in light of the incredible progress made over the past 5 years in Peptide drug technology.
Great that she is still on board imho.
It will come good in your lifetime
2024 has to be the year... We live in hope!
For our testing co to give an update but I doubt whether it would be made public anyway. Holding for the Lupuzor approval and with it the mega bagger! Hope it happens in my lifetime!!
Holding much better today
It is interesting that Lanstead hasn't been selling since it announced its revised holding of 15.89% on the 28th December 2023.
It is required to notify if its holding goes below 15% under Stock Exchange rules so it appears content to hold for now .
Obviously any further increases in the Immupharma SP means more Lanstead cash into the business as per the Subscription Agreement.
The issue of the warrants is also interesting.
Now if only management can provide the market with some positive news on commercial deals and the Lupuzor trial timelines , we would be on our way.
Fingers crossed for timely newsflow in the coming weeks.
ATB
They are putting buyers off with the spread